Asimov
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Brookline Ave Ste 1201, Boston, Mass...Phone Number
(617) 658-3622Website
www.asimov.comRevenue
$14.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
3
1
1
About Asimov
About Asimov: Asimov is the synthetic biology company building a full-stack genetic design platform to program living cells. Asimov's multi-disciplinary team combines genetic engineering, design automation, and artificial intelligence to enable new applications in molecular manufacturing and therapeutics.Explore more
Asimov Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Asimov your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Asimov recently announced quarterly report
Product Launch: Get notified when Asimov launches new products
Funding: Get notified immidiatlly once Asimov has new funding data
Click to see if Asimov had a recent Job posting/layoffs
Asimov, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Asimov has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Asimov
Website visits: Recent activity has been detected on your website
Check out if Asimov is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Asimov
Compare insights from companies similar to Asimov, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Asimov is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Asimov is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Asimov.
Asimov financials insights
Gather financial insights about Asimov, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$4.7M
2023
Series B
$175M
Asimov Tech Stack
A closer look at the technologies used by Asimov
Most Recent Scoops
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Open Position
Event
Product Marketing, Events, Sales, Search, Laboratory Operations, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Asimov News & Media
Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
RNA Edge combines AI sequence optimization, novel genetic parts, and validation in application-relevant cell models to improve expression and half-life.Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
Asimov partners with Score Pharma to develop biosuperior antibody therapeutics with enhanced ADCC activity using Asimov's CHO Edge platform.Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics (“RevOpsis”), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies. This agreement follows a successful cell line development campaign with Asimov’s CHO Edge System for the lead RevOpsis asset, RO-104. UndeAsimov Launches AAV Edge, a Suite of AI Models, Host Cells, and Genetic Tools for End-to-End Gene Therapy Development
BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools for adeno-associated viral (AAV) gene therapy design and manufacturing. The system provides gene therapy developers a single access point to an array of best-in-class tools to supercharge gene therapy development. While gene therapy holds significant promise for treating otherwise intractable disease
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Asimov
Sign Up For FreeTo access detailed company insights
About Asimov: Asimov is the synthetic biology company building a full-stack genetic design platform to program living cells. Asimov's multi-disciplinary team combines genetic engineering, design automation, and artificial intelligence to enable new applications in molecular manufacturing and therapeutics.... Read More
